Erasca Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-19.5%projected annual EPS growth
Analyst Coverage
10analysts covering
FY EPS (est.)
-$0.97next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| ERAS-4001 Preliminary Phase 1 Monotherapy Data Readout (BOREALIS-1) | 31 Dec 2026 |
| ERAS-0015 Monotherapy Expansion and Combination Dose Escalation Data (AURORAS-1) | 30 Jun 2027 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly408.5MTarget: Sufficient to fund operations into H2 2028
ERAS-0015 Objective Response Rate (ORR) in RAS-driven G12X NSCLC Annually62.0%Target: Maintain >60% ORR in expansion cohorts
ERAS-0015 Grade 3+ Rash Rate Annually2.0%Target: <5% to demonstrate best-in-class tolerability
Watch Items
- Revolution Medicines Intellectual Property LitigationTrigger: Court rulings or preliminary injunctions regarding ERAS-0015 patent validity and trade secret misappropriationAction: Assess impact on ERAS-0015 development timeline and evaluate potential design-around options or settlement terms
- ERAS-0015 Treatment-Related Serious Adverse Events (Pneumonitis)Trigger: Pneumonitis rate exceeding 3% or additional treatment-related deaths in AURORAS-1Action: Review dose modification protocols and patient selection criteria with the Scientific Advisory Board
- ERAS-4001 Phase 1 Monotherapy Safety and EfficacyTrigger: Initial Phase 1 monotherapy data readout in H2 2026Action: Compare therapeutic window and target coverage against competitor pan-KRAS inhibitors to determine expansion cohort strategy
Research as of 19 Jun 2026